Acquisition Worries

Bayer’s Pharma Commitment

Bayer hq Bayer
Bayer is and will remain a maker of drugs, according to CEO Werner Baumann.
  • Why it matters

    Why it matters

    Bayer’s $66-billion (€59 billion) purchase of the world’s largest producer of seeds begs the question whether Bayer’s pharmaceutical business will suffer as a result.

  • Facts


    • The Bayer-Monsanto deal faces scrutiny by antitrust authorities and investors.
    • Leverkusen-based Bayer seeks regulatory approval in 20-plus countries and expects the deal to be concluded by the end of 2017.
    • Many Bayer employees, especially those in its pharmaceutical division, fear the company has bitten off more than it can chew in its takeover of the U.S. agrochemicals giant.
  • Audio


  • Pdf

Finally, it was the workers’ turn.

Last Wednesday, Bayer chief executive Werner Baumann and board member Liam Condon had dozens of interviews about the purchase of American seeds and pesticides maker Monsanto. The executives from German drugs and pesticides maker Bayer spoke via webcast from a conference room in New York to their workers in Leverkusen, its headquarters, and Monheim, the main seat of its agrochemicals business.

The Bayer workers asked a lot of questions and touched on some tricky points. What does this mean for their jobs? How will management deal with criticism by environmental associations? And how does management see the monopoly problem?

Want to keep reading?

Subscribe now or log in to read our coverage of Europe’s leading economy.